The previous pieces in this series looked at the coverage gap from the outside: what it costs companies to be uncovered, and what they can do about it. This piece looks at the same question from the other side of the table.
Earlier chapters covered the reasons an analyst might decline to initiate on a new name:
- Capacity constraints on the team
- A market cap or trading volume that is too small
- Too many analysts already covering the stock
- Research economics that do not work at a full-service bank without investment banking revenue potential
Those friction points are real, and for the right analyst or research team, picking up coverage of a previously uncovered company can also be a genuinely attractive opportunity.
Differentiation in a crowded biopharma research universe
According to FactSet, 1,564 publicly traded healthcare companies across 40+ global markets have no analyst coverage (as of August 2026). They compete for institutional attention without a research foundation. For an analyst who initiates on one of them, there is opportunity to own a name before the crowd arrives.
Large-cap healthcare companies attract 20 to 30 analysts, and another voice on Eli Lilly rarely moves the needle for anyone. Being the first analyst to initiate on a promising oncology biotech with a $400 million market cap, ahead of a catalyst, creates differentiation the market notices.
Institutional investors pay close attention to analysts who surface interesting ideas before they become consensus. The annual broker vote process, through which institutions allocate commission payments to reward the research they find most valuable, favors analysts who bring new investment ideas over those who cover the same names better than their competitors.
A well-timed initiation on a previously uncovered name builds an analyst’s reputation for original thinking in a way that incremental improvements to large-cap coverage cannot.
Conferences and investor access
Healthcare investor conferences are another place where initiating on new names creates compounding returns for an analyst’s franchise.
A covered company is much more likely to present at the analyst’s firm’s conferences and take part in one-to-one meetings with institutional clients. Every new name an analyst adds to a coverage list can add a company to the conference program, and institutional investors choose which conferences to attend based substantially on which companies they can meet.
An analyst who covers a broader range of interesting companies, including emerging names not yet on every competitor’s list, offers investors more meetings with companies they care about in fewer trips. That calculus directly affects conference attendance, institutional relationships, and the revenue those conferences generate.
Buy-side investors have become increasingly explicit about this. Panels at TWST Events in London in July 2026 and Substantive Research in New York in June 2026 delivered the same message from institutional investors: in-person, non-deal roadshows with management teams are the most important part of their investment process, and they value and pay most for the research services that facilitate that access best.
If picking up coverage of a new company results in non-deal roadshows to key institutional clients, the revenue and broker vote implications are direct and measurable.
The case for a different calculus
The structural case against initiating on small, uncovered companies is well established. Liquidity constraints, initiation costs, and the economics of bulge-bracket research all point in the same direction. Set against them, the right uncovered company at the right point in its development offers:
- Differentiation from owning a name before the crowd arrives
- Access to conferences and institutional meetings
- Stronger relationships with institutional investors
- The potential to be first on a name that grows into a significant position for multiple institutional clients
Together these are the ingredients of a high-performing research franchise. The coverage gap exists in part because most research teams underweight them when making coverage decisions. That is starting to change.
This is the fourth piece in our series on the healthcare coverage gap. Next: the investor conference circuit and how it connects coverage to capital.
